ArticleNano letters2026
Spectral Super-Resolution Colloidal SERS Spectroscopy for Multiplexed Detection of Protein Biomarkers.
Article in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Surface-enhanced Raman spectroscopy (SERS) possesses molecular specificity and single-molecule sensitivity. Yet, intensity-based SERS assays are vulnerable to nontarget analyte-induced intensity fluctuations, while frequency-shift-based SERS assays are constrained by the instrument's spectral resolution, limiting the translational quantitative applications of SERS. Herein, we introduce a stochastic colloidal plasmon-enhanced spectral sampling (SCOPE) strategy for spectral super-resolution SERS spectroscopy. Through large-scale stochastic spectral sampling in a chemically homogeneous, spectrally dynamic colloidal solution containing plasmonic nanoparticles and analyte molecules, we obtain an empirical approximation of the probability density function of the sample's spectral response. This enables accurate estimation of the true peak center with subresolution precision through Gaussian histogram fitting. Building on SCOPE, we develop a spectrally super-resolved colloidal SERS immunoassay for multiplexed detection of a panel of protein biomarkers spanning endocrine, cardiovascular, and hemostatic conditions. We believe this study paves the way for spectrally super-resolved spectroscopic applications in a variety of analytical domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.